(By Sharon Begley for STAT)
Beneath the technical and legal jargon in the latest documents filed in the battle over CRISPR patents is a simple argument that, in only slightly exaggerated form, comes down to this: Continue reading article here…..
Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.